|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM309441242 |
| 003 |
DE-627 |
| 005 |
20231225133923.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2020.108450
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1031.xml
|
| 035 |
|
|
|a (DE-627)NLM309441242
|
| 035 |
|
|
|a (NLM)32360516
|
| 035 |
|
|
|a (PII)S1521-6616(20)30331-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Mastaglio, Sara
|e verfasserin
|4 aut
|
| 245 |
1 |
4 |
|a The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 23.06.2020
|
| 500 |
|
|
|a Date Revised 10.01.2021
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2020 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Acute respiratory distress syndrome (ARDS) is a devastating clinical manifestation of COVID-19 pneumonia and is mainly based on an immune-driven pathology. Mounting evidence suggests that COVID-19 is fueled by a maladaptive host inflammatory response that involves excessive activation of innate immune pathways. While a "cytokine storm" involving IL-6 and other cytokines has been documented, complement C3 activation has been implicated as an initial effector mechanism that exacerbates lung injury in preclinical models of SARS-CoV infection. C3-targeted intervention may provide broader therapeutic control of complement-mediated inflammatory damage in COVID-19 patients. Herein, we report the clinical course of a patient with severe ARDS due to COVID-19 pneumonia who was safely and successfully treated with the compstatin-based complement C3 inhibitor AMY-101
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antiviral Agents
|2 NLM
|
| 650 |
|
7 |
|a Complement C3
|2 NLM
|
| 650 |
|
7 |
|a Complement Inactivating Agents
|2 NLM
|
| 650 |
|
7 |
|a Peptides, Cyclic
|2 NLM
|
| 650 |
|
7 |
|a compstatin
|2 NLM
|
| 700 |
1 |
|
|a Ruggeri, Annalisa
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Risitano, Antonio M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Angelillo, Piera
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yancopoulou, Despina
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Mastellos, Dimitrios C
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Huber-Lang, Markus
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Piemontese, Simona
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Assanelli, Andrea
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Garlanda, Cecilia
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lambris, John D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ciceri, Fabio
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 215(2020) vom: 15. Juni, Seite 108450
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:215
|g year:2020
|g day:15
|g month:06
|g pages:108450
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2020.108450
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 215
|j 2020
|b 15
|c 06
|h 108450
|